key: cord-0925743-bp787eaz authors: Cruz, Tamara; Mendoza, Núria; Perea, Lídia; Albacar, Núria; Gonzalez, Azucena; Hernandez-Gonzalez, Fernanda; Juan, Manel; Agustí, Alvar; Sellares, Jacobo; Sibila, Oriol; Faner, Rosa title: SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung SEQUELAE date: 2022-02-11 journal: ERJ Open Res DOI: 10.1183/23120541.00706-2021 sha: df305ea0622946dfc603047d51dc92b497ff875f doc_id: 925743 cord_uid: bp787eaz Patients infected by SARS-CoV-2 may develop pneumonia (COVID19) and require hospital admission and, eventually, critical care [1]. This has been related with a weaker innate immune response with impaired production of type I interferons [2]. In this setting, an antigen specific T-cell response is needed for the elimination of SARS-CoV-2, as well as to develop long-lasting memory to respond to potential future SARS-CoV-2 infections [3, 4]. However, this response needs to be contained once the virus is eradicated to avoid further damaging the host. Patients infected by SARS-CoV-2 may develop pneumonia (COVID19) and require hospital admission and, eventually, critical care (1) . This has been related with a weaker innate immune response with impaired production of type I interferons (2) . In this setting, an antigen specific T-cell response is needed for the elimination of SARS-CoV-2, as well as to develop long-lasting memory to respond to potential future SARS-CoV-2 infections (3, 4) . However, this response needs to be contained once the virus is eradicated to avoid further damaging the host. Several studies have characterized the SARS-CoV-2 T-cell response in patients recovering from COVID-19 and showed that the intensity of the T-cell response relates to the severity of the acute pneumonia episode (5, 6) . Moreover, the severity of the disease is a risk factor for potential lung sequelae in COVID-19 survivors (7) . We recently reported that up to 57% of COVID-19 survivors present lung function abnormalities, particularly reduced carbon monoxide lung diffusion capacity (DLCO), three months after hospital discharge (8) . The relationship between the persistence of the specific T-cell response elicited during the acute COVID-19 episode and lung function abnormalities during follow-up is unknown. To investigate these questions, we contrasted the in vitro T-cell response against the SARS-COV-2 Spike (S) and the Nucleocapside (N) proteins, two well recognized viral antigens, in COVID-19 convalescent patients with normal and abnormal DLCO 6 months after hospital discharge. This prospective, observational study included 25 adults who were hospitalized in our institution because of PCR-confirmed COVID-19 pneumonia and were studied at 6 months after hospital discharge. Participants were categorized according to their intensive care unit (ICU) admission (or not) during the acute COVID-19 episode, or by their DLCO value 6 months after discharge (normal using Mann-Whitney tests and analyses were performed using R version 3.6.1 or GraphPad Prism 7 (La Jolla, Calif). A limitation of the study is the lack of lung function prior the COVID-19 episode, but only one patient in our study had a diagnosis of a lung condition (asthma) prior the COVID episode, and was not related to low levels of DLCO (Table 1) . We studied 23 patients (61% males) with a mean age of 60.0 ± 10.5 years; 10 of them (43%) needed critical care during the acute COVID-19 episode, and 14 of them (61%) had DLCO <80% ref. six months after discharge. Table 1 Table 1 ). The CD4 TEMRA and IFNɣ producing cells against the S peptide and the CD8 TEM y TEMRA against the S and N peptides, were increased in patients requiring critical care during the acute COVID-19 episode ( Table 1 ). The CD8 IFNɣ response was reduced in patients with abnormal DLCO at convalescence and presented a reduced proportion of CD4 TEMRA cells (Table 1 ). This study shows that a T-cell specific response persists in the majority (87%) of COVID-19 patients 6-months after hospital discharge. This response is more prominent in those who required critical care during the acute COVID-19 episode, suggesting that the severity of the acute episode determined a more robust virus specific T-cell expansion. We also observed that the presence of reduced DLCO 6 months after discharge is related to a decrease in SARS-CoV-2 specific IFNɣ producing CD8 T cells. Also, upon antigen stimulation, these patients presented a reduced expansion of cells with TEMRA phenotype, suggesting a tighter control of the differentiation from memory cells towards the effector, or the requirement of a costimulatory signal (10) . Further studies are required to elucidate these mechanisms and implications of these observations. Authors thank all participants in the study for the willingness to contribute to medical research, and all field workers for their dedication and quality of their daily work. We are indebted to the HCB- Soler for its support to the COVIDBANK collection. Covid-19 CMTEGf. Clinical Characteristics of Coronavirus Disease 2019 in China Interplay between SARS-CoV-2 and the type I interferon response Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) COVID-19: immunopathology and its implications for therapy Consortium OINC-RTc, Investigators IC. Broad and strong memory CD4 + and CD8 + T-cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Pan-Hammarström Q. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge Standardization of Spirometry Effector and memory T-cell differentiation: implications for vaccine development